Literature DB >> 1284932

Performance assessment of neonatal dried blood spot testing for HIV antibody.

J V Parry, P P Mortimer, A G Nicoll.   

Abstract

A study was undertaken to assess the performance of laboratories participating in the UK unlinked anonymised neonatal screening programme for the detection of HIV antibody. A coded panel of 100 contrived dried blood spots prepared form well characterised anti-HIV-1 and anti-HIV-2 positive sera and an anti-HIV negative serum was distributed to eight testing centres. Fifty-one out of 52 anti-HIV-1 positive samples were identified by all eight laboratories: five laboratories identified all 52 specimens. Only one laboratory detected all four anti-HIV-2 positive spots. None of the laboratories reported a seronegative spot as reactive. The sensitivity of anonymised neonatal anti-HIV-1 screening was deemed satisfactory in all participating laboratories but the margin of sensitivity was insufficient to allow pooling of dried blood spot eluates before testing. Technical modifications would be necessary to increase sensitivity for anti-HIV-2 were HIV-2 infection to be reported more frequently in the UK. Performance assessment of the screening programme should be repeated at regular intervals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1284932

Source DB:  PubMed          Journal:  Commun Dis Rep CDR Rev        ISSN: 1350-9349


  3 in total

Review 1.  The use of the dried blood spot sample in epidemiological studies.

Authors:  S P Parker; W D Cubitt
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

2.  HIV testing updates and challenges: when regulatory caution and public health imperatives collide.

Authors:  Bernard M Branson
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

3.  Measuring HIV-1 seroprevalence among English newborns: blood spot size.

Authors:  C McGarrigle; J Parry; A Nicoll
Journal:  Am J Public Health       Date:  1993-12       Impact factor: 9.308

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.